Technical Snapshots for These Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, Moleculin Biotech, and TG Therapeutics

Friday, November 17, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 17, 2017 /PRNewswire/ -- If you want a Stock Review on DVAX, KERX, MBRX, or TGTX then come over to

and sign up for your free customized report. Biotech companies are mainly involved in developing new drug treatments, tests, and other medical technologies. The sector is notoriously volatile in large part, because investors are often banking on a firm's
latest drug or treatment receiving regulatory approval where the chances of success are low. For today, research reports have been issued by on Dynavax Technologies Corp. (NASDAQ: DVAX), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Moleculin Biotech Inc. (NASDAQ: MBRX), and TG Therapeutics Inc. (NASDAQ: TGTX). Access's complimentary reports for today's stocks line-up at:

Dynavax Technologies

Shares in Berkeley, California headquartered Dynavax Technologies Corp. rose 3.36%, ending Thursday's trading session at $18.45. The stock recorded a trading volume of 1.87 million shares. The Company's shares have gained 13.89% over the last three months and 367.09% on an YTD basis. The stock is trading 59.52% above its 200-day moving average. Moreover, shares of Dynavax Technologies, which focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation, have a Relative Strength Index (RSI) of 38.53.  

On November 09th, 2017, Dynavax Technologies announced that the US Food and Drug Administration has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV-B is the first new hepatitis B vaccine in the US in more than 25 years and the only two-dose hepatitis B vaccine for adults. Visit us today and access your complete report on DVAX for free at:

Keryx Biopharmaceuticals

Boston, Massachusetts headquartered Keryx Biopharmaceuticals Inc.'s stock dropped 3.18%, closing the day at $4.87. A total volume of 2.83 million shares was traded, which was above their three months average volume of 1.70 million shares. The Company's shares are trading 23.66% below their 200-day moving average. Additionally, shares of Keryx Biopharma, which focuses on providing medicines for patients with renal disease in the US, have an RSI of 35.49. 

On November 07th, 2017, Keryx Biopharmas announced that the US FDA has approved Auryxia for an additional indication. The approval is for the treatment of iron deficiency anemia in adults with chronic kidney disease, not on dialysis. Auryxia was originally approved in September 2014 for the control of serum phosphorus levels in people with chronic kidney disease who require dialysis. The complimentary research report on KERX can be accessed at:

Moleculin Biotech

On Thursday, shares in Houston, Texas headquartered Moleculin Biotech Inc. recorded a trading volume of 182,887 shares. The stock ended the day 1.87% higher at $1.63. The Company's shares are trading below their 200-day moving average by 0.44%. Furthermore, shares of Moleculin Biotech, which focuses on the development of anti-cancer drug candidates, have an RSI of 36.38.  

On November 01st, 2017, Moleculin Biotech announced that responses to US FDA requests for additional information relating to the physician-sponsored Investigational New Drug ("IND") application to study WP1066 as a potential treatment for brain tumors have been submitted. As the Company has disclosed previously, the IND had been placed on clinical hold pending satisfactory responses to questions provided by the FDA. Register for free on and download the research report on MBRX at:

TG Therapeutics

New York headquartered TG Therapeutics Inc.'s stock declined 1.78%, finishing yesterday's session at $8.30. A total volume of 2.09 million shares was traded, which was above their three months average volume of 1.21 million shares. The Company's shares have advanced 4.40% in the last one month and 78.49% on an YTD basis. The stock is trading below its 50-day moving average by 18.27%. Additionally, shares of TG Therapeutics, which focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the US, have an RSI of 44.36.  

On November 08th, 2017, TG Therapeutics announced its financial results for the three months ended September 30th, 2017. R&D expenses for Q3 2017 were $27.1 million, G&A expenses were $4.5 million, and net loss was $31.5 million. Cash, cash equivalents, investment securities, and interest receivable were $91.8 million as of September 30th, 2017.

On November 14th, 2017, research firm H.C. Wainwright resumed its 'Buy' rating on the Company's stock, with a target price of $33 per share. Get free access to your research report on TGTX at:

Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


View original content:

SOURCE Morris Capital Inc

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store